160 related articles for article (PubMed ID: 17951911)
21. Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease.
Wong LJ; Desai RU; Jain A; Feliciano D; Moshfeghi DM; Sanislo SR; Blumenkranz MS
Retina; 2008 Oct; 28(8):1151-8. PubMed ID: 18685542
[TBL] [Abstract][Full Text] [Related]
22. Acute retinal pigment epithelial tear in the untreated fellow eye following repeated bevacizumab (Avastin) injections.
Mennel S; Callizo J; Schmidt JC; Meyer CH
Acta Ophthalmol Scand; 2007 Sep; 85(6):689-91. PubMed ID: 17403025
[No Abstract] [Full Text] [Related]
23. Retinal pigment epithelial tear after ranibizumab therapy for subfoveal fibrovascular pigment epithelial detachment.
Chan CK; Lin SG
Eur J Ophthalmol; 2007; 17(4):674-6. PubMed ID: 17671950
[TBL] [Abstract][Full Text] [Related]
24. Retinal pigment epithelial tear following intravitreal ranibizumab injections for neovascular age-related macular degeneration.
Lee GK; Lai TY; Chan WM; Lam DS
Graefes Arch Clin Exp Ophthalmol; 2007 Aug; 245(8):1225-7. PubMed ID: 17287977
[TBL] [Abstract][Full Text] [Related]
25. Retinal pigment epithelium tears after bevacizumab injection.
Yeh B; Ferrucci S
Optometry; 2011 Mar; 82(3):152-7. PubMed ID: 21130699
[TBL] [Abstract][Full Text] [Related]
26. Retinal pigment epithelial tear following intravitreal bevacizumab.
Bakri SJ; Patel SP
Eye (Lond); 2007 Mar; 21(3):424-5. PubMed ID: 17187026
[No Abstract] [Full Text] [Related]
27. Pigment epithelial tears associated with anti-VEGF therapy: incidence, long-term visual outcome, and relationship with pigment epithelial detachment in age-related macular degeneration.
Doguizi S; Ozdek S
Retina; 2014 Jun; 34(6):1156-62. PubMed ID: 24296398
[TBL] [Abstract][Full Text] [Related]
28. Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration.
Ach T; Hoeh AE; Ruppenstein M; Kretz FT; Dithmar S
Retina; 2010 Oct; 30(9):1420-5. PubMed ID: 20543764
[TBL] [Abstract][Full Text] [Related]
29. Retinal pigment epithelial tears after pegaptanib injection for exudative age-related macular degeneration.
Singh RP; Sears JE
Am J Ophthalmol; 2006 Jul; 142(1):160-2. PubMed ID: 16815269
[TBL] [Abstract][Full Text] [Related]
30. Intravitreal bevacizumab for exudative age-related macular degeneration: effect on different subfoveal membranes.
Tao Y; Jonas JB
Retina; 2010 Oct; 30(9):1426-31. PubMed ID: 20539255
[TBL] [Abstract][Full Text] [Related]
31. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
32. Tears of the retinal pigment epithelium: an old problem in a new era.
Chang LK; Sarraf D
Retina; 2007 Jun; 27(5):523-34. PubMed ID: 17558312
[TBL] [Abstract][Full Text] [Related]
33. Retinal pigment epithelial tear following intravitreal bevacizumab for choroidal neovascular membrane due to age-related macular degeneration.
Hannan SR; Madhusudhana KC; Lotery AJ; Newsom RS
Br J Ophthalmol; 2007 Jul; 91(7):977-8. PubMed ID: 17576713
[No Abstract] [Full Text] [Related]
34. Retinal pigment epithelium tears following intravitreal ranibizumab therapy.
Kiss C; Michels S; Prager F; Geitzenauer W; Schmidt-Erfurth U
Acta Ophthalmol Scand; 2007 Dec; 85(8):902-3. PubMed ID: 17408387
[TBL] [Abstract][Full Text] [Related]
35. Intravitreal bevacizumab for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration.
Bom Aggio F; Eid Farah M; Melo GB
Acta Ophthalmol Scand; 2006 Oct; 84(5):713-4. PubMed ID: 16965511
[No Abstract] [Full Text] [Related]
36. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration in treatment-naive patients.
Pedersen KB; Sjølie AK; Møller F
Acta Ophthalmol; 2009 Nov; 87(7):714-9. PubMed ID: 19094171
[TBL] [Abstract][Full Text] [Related]
37. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
[TBL] [Abstract][Full Text] [Related]
38. Retinal pigment epithelial tears and the management of exudative age-related macular degeneration.
Barkmeier AJ; Carvounis PE
Semin Ophthalmol; 2011 May; 26(3):94-103. PubMed ID: 21609221
[TBL] [Abstract][Full Text] [Related]
39. Bevacizumab for occult subfoveal neovascularization in age-related macular degeneration.
Jonas JB; Harder B; Spandau UH; Kamppeter BA; Libondi T; Sauder G
Eur J Ophthalmol; 2006; 16(5):774-5. PubMed ID: 17061237
[TBL] [Abstract][Full Text] [Related]
40. Foveal RPE autofluorescence as a prognostic factor for anti-VEGF therapy in exudative AMD.
Heimes B; Lommatzsch A; Zeimer M; Gutfleisch M; Spital G; Bird AC; Pauleikhoff D
Graefes Arch Clin Exp Ophthalmol; 2008 Sep; 246(9):1229-34. PubMed ID: 18509668
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
